Syneron Bio Secures Nearly $100M Series A Funding for Macrocyclic Peptide Platform
核心洞察
Syneron Bio (搜索) successfully completed Series A and A+ financing rounds, raising close to $100 million from top-tier investors including AstraZeneca and Pfizer.
The funding will strengthen development of the company's proprietary Synova™ platform for intelligent high-throughput macrocyclic peptide (搜索) drug discovery.
The Beijing-based biotech company has built a robust pipeline targeting oncology (搜索) and chronic diseases (搜索) using next-generation macrocyclic peptide (搜索) therapeutics.
Syneron Bio (搜索), a Beijing-based macrocyclic peptide (搜索) drug discovery company, has successfully closed nearly $100 million in Series A and A+ financing rounds, marking a significant milestone for the biotech firm's proprietary drug development platform. The funding round attracted participation from leading global pharmaceutical companies and top-tier investment institutions, including AstraZeneca, AZ-CICC Healthcare Investment Fund, Pfizer Biotech Development Investment Fund, GL Ventures, 5Y Capital, Sinovation Capital, Lenovo Capital, Gree Capital and KHK fund.
Strategic Investment from Major Pharma Players
The participation of major pharmaceutical companies AstraZeneca and Pfizer through their respective investment arms signals strong industry confidence in Syneron Bio (搜索)'s approach to macrocyclic peptide (搜索) therapeutics. This strategic backing provides not only financial resources but also potential collaboration opportunities with established pharmaceutical giants.
Dr. Xiao Zhang, Founder and CEO of Syneron Bio (搜索), expressed appreciation for the investor support, stating: "We are honored to receive the recognition and support of leading global pharmaceutical companies and top-tier investment institutions. This financing will significantly strengthen the development of our intelligent high-throughput macrocyclic peptide (搜索) development platform, Synova™, and provide the resources needed to advance multiple pipelines toward clinical stages."
Advancing the Synova™ Platform
The funding will be directed toward strengthening the development of Syneron Bio (搜索)'s proprietary Synova™ platform, which employs intelligent high-throughput technology for macrocyclic peptide (搜索) drug discovery. This platform represents the company's core technological advantage in developing next-generation macrocyclic peptide therapeutics.
Syneron Bio (搜索) has built a robust pipeline targeting oncology (搜索) and chronic diseases (搜索) using its macrocyclic peptide (搜索) approach. The company combines expertise in drug development with data science capabilities to advance its therapeutic programs.
Rapid Growth Trajectory
The successful completion of this funding round demonstrates Syneron Bio (搜索)'s rapid growth trajectory, having completed multiple rounds of equity financing in less than three years since its establishment. This achievement reflects the company's ability to attract backing from multiple leading venture capital funds and validates the potential of its drug discovery platform.
The company's focus on macrocyclic peptide (搜索) therapeutics positions it in an emerging area of drug development that combines the specificity of biologics with the drug-like properties of small molecules, potentially offering advantages in treating complex diseases across oncology (搜索) and chronic disease indications.